On this page
Back to topElectra Therapeutics ETRA
Electra Therapeutics listed on Nasdaq on 18 Sep 2026 and is not in the S&P 500. It is worth $562 million. Its price history starts on 18 Sep 2026. Its board is not in our data yet.
- CEO
- Quehuong (Kathy) Dong
- Listed
- 18 Sep 2026 on Nasdaq, IPO filings and terms
- Headquarters
- South San Francisco, CA
- Market cap
- $562M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Electra Therapeutics' market cap since September 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $560M |
Download Electra Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 18 Sep 2026.
Board and leadership
Board and officers
Electra Therapeutics' board is not in our data yet. It listed on 18 Sep 2026 and has not filed a proxy statement. See its 8-K filings.
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $24.3 million in 7 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 10 Nov 2026Buy | Carl L. GordonDirector | $192K |
| 9 Nov 2026Buy | Carl L. GordonDirector | $165K |
| 6 Nov 2026Buy | Carl L. GordonDirector | $388K |
| 5 Nov 2026Buy | Carl L. GordonDirector | $1.1M |
| 4 Nov 2026Buy | Carl L. GordonDirector | $537K |
| 3 Nov 2026Buy | Carl L. GordonDirector | $1.9M |
| 21 Sep 2026Buy | Carl L. GordonDirector | $20M |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Electra Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.